Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

August 25, 2027

Study Completion Date

August 25, 2027

Conditions

Refractory/Relapse NeuroblastomaPediatric Solid Tumors

Interventions

BIOLOGICAL

Biological

Intravenous injection of GAIA-102 alone

BIOLOGICAL

Biological

Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination

BIOLOGICAL

Biological

Intravenous injection of GAIA-102 with nivolumab combination

Trial Locations (1)

RECRUITING

Kyushu University Hospital, Fukuoka

All Listed Sponsors

lead

Kyushu University

OTHER